Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetically engineered vaccines.

Wayne R Thomas1, Belinda J Hales, Wendy-Anne Smith

  • 1Centre for Child Health Research, University of Western Australia, Telethon Institute for Child Health Research, PO Box 855, West Perth 6872, 100 Roberts Road, Subiaco 6008, Western Australia. wayne@ichr.uwa.edu.au

Current Allergy and Asthma Reports
|April 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Linking the westernised oropharyngeal microbiome to the immune response in Chinese immigrants.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology·2020
Same author

Toll-like receptor signalling has inverted U-shaped response over time with the Western environment.

Allergy·2020
Same author

Differential Gene Expression of Lymphocytes Stimulated with Rhinovirus A and C in Children with Asthma.

American journal of respiratory and critical care medicine·2020
Same author

Effects of Ser47-Point Mutation on Conformation Structure and Allergenicity of the Allergen of Der p 2, a Major House Dust Mite Allergen.

Allergy, asthma & immunology research·2018
Same author

A marked shift in innate and adaptive immune response in chinese immigrants living in a western environment.

Allergy·2018
Same author

WHO/IUIS Allergen Nomenclature: Providing a common language.

Molecular immunology·2018
Same journal

Harnessing Machine Learning and Electronic Health Record Data to Improve Asthma Management.

Current allergy and asthma reports·2026
Same journal

Incorporating New Guidelines into School-Based Asthma Management.

Current allergy and asthma reports·2026
Same journal

The Modern Environment and Childhood Asthma: The Role of Air Pollution and Heavy Metal Exposure.

Current allergy and asthma reports·2026
Same journal

Targeting Type 2 and Non-type 2 Asthma: Emerging Biologics and Personalized Strategies.

Current allergy and asthma reports·2026
Same journal

The Role of the Indoor Exposome in Food Allergy Development.

Current allergy and asthma reports·2026
Same journal

Understanding Infantile Atopic Dermatitis: A Review of Environmental, Familial, Genetic and Microbial Influences.

Current allergy and asthma reports·2026
See all related articles

Recombinant DNA technology enables the creation of novel allergy vaccines. Genetically engineered hypoallergenic vaccines show promise in reducing allergenicity while retaining immune response, setting a benchmark for future allergy treatments.

Area of Science:

  • Biotechnology
  • Immunology
  • Allergen Research

Background:

  • Recombinant DNA technology offers new avenues for developing allergy vaccines.
  • Traditional approaches focused on synthetic peptides representing specific epitopes.

Purpose of the Study:

  • To explore genetically engineered allergens as hypoallergenic vaccines.
  • To evaluate the efficacy of these hypoallergens in reducing allergenicity and maintaining immune stimulation.

Main Methods:

  • Production of hypoallergenic vaccines using genetically engineered allergens.
  • Demonstration of reduced allergenicity via skin and nasal provocation tests.
  • Assessment of T cell-stimulating activity and antibody production (IgE and IgG).

Main Results:

Related Experiment Videos

  • Hypoallergenicity demonstrated through reduced immunoglobulin E (IgE) binding and provocation tests.
  • Retention of T cell-stimulating activity and induction of anti-allergen IgG antibodies.
  • Clinical trials showed modification of IgE/IgG production, skin reactivity, and symptoms.

Conclusions:

  • Genetically engineered hypoallergenic vaccines, like those based on Bet v 1, are effective in reducing allergic responses.
  • This represents a significant advancement, setting a benchmark for future recombinant allergy vaccines.
  • New generations of hypoallergens are being developed based on structural and epitope knowledge for broader applications.